Aquestive Therapeutics Inc. (AQST) upgraded Issued by Wall Street Gurus

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp

Aquestive Therapeutics Inc. (NASDAQ:AQST) went down by -4.64% from its latest closing price compared to the recent 1-year high of $9.47. The company’s stock price has collected 5.35% of gains in the last five trading sessions. Press Release reported 9 hours ago that AQST INVESTOR FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion In a Securities Class Action Against Aquestive Therapeutics, Inc.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Is It Worth Investing in Aquestive Therapeutics Inc. (NASDAQ :AQST) Right Now?

Opinions of the stock are interesting as 6 analysts out of 6 who provided ratings for Aquestive Therapeutics Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”


The 2021 Backdoor Crypto Portfolio (free)

Even if you’re not actively in crypto, you deserve to know what’s actually going on...

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.

Sponsored



The average price from analysts is $14.67. AQST currently public float of 29.64M and currently shorts hold a 8.26% ratio of that float. Today, the average trading volume of AQST was 976.29K shares.

AQST’s Market Performance

AQST stocks went up by 5.35% for the week, with a monthly jump of 11.03% and a quarterly performance of -20.24%, while its annual performance rate touched 124.17%. The volatility ratio for the week stands at 10.52% while the volatility levels for the past 30 days are set at 9.13% for Aquestive Therapeutics Inc.. The simple moving average for the period of the last 20 days is -3.82% for AQST stocks with a simple moving average of -20.09% for the last 200 days.

Analysts’ Opinion of AQST

Many brokerage firms have already submitted their reports for AQST stocks, with RBC Capital Mkts repeating the rating for AQST by listing it as a “Outperform.” The predicted price for AQST in the upcoming period, according to RBC Capital Mkts is $7 based on the research report published on April 07th of the current year 2021.

Lake Street gave a rating of “Buy” to AQST, setting the target price at $14 in the report published on January 03rd of the previous year.

AQST Trading at -10.00% from the 50-Day Moving Average

After a stumble in the market that brought AQST to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -50.03% of loss for the given period.

Volatility was left at 9.13%, however, over the last 30 days, the volatility rate increased by 10.52%, as shares surge +5.82% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -16.28% lower at present.

During the last 5 trading sessions, AQST rose by +5.35%, which changed the moving average for the period of 200-days by -13.37% in comparison to the 20-day moving average, which settled at $4.93. In addition, Aquestive Therapeutics Inc. saw -11.59% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at AQST starting from Schobel Alexander Mark, who sale 23,460 shares at the price of $6.75 back on Feb 10. After this action, Schobel Alexander Mark now owns 837,000 shares of Aquestive Therapeutics Inc., valued at $158,355 using the latest closing price.

Schobel Alexander Mark, the Chief Innovation/Tech Officer of Aquestive Therapeutics Inc., sale 11,540 shares at $6.75 during a trade that took place back on Feb 09, which means that Schobel Alexander Mark is holding 860,460 shares at $77,895 based on the most recent closing price.

Stock Fundamentals for AQST

Current profitability levels for the company are sitting at:

  • -93.55 for the present operating margin
  • +71.72 for the gross margin

The net margin for Aquestive Therapeutics Inc. stands at -121.67. The total capital return value is set at -90.14, while invested capital returns managed to touch -123.39. Equity return is now at value 175.40, with -92.50 for asset returns.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

When we switch over and look at the enterprise to sales, we see a ratio of 5.18, with the company’s debt to enterprise value settled at 0.38. The receivables turnover for the company is 4.57 and the total asset turnover is 0.65. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.11.

Sign up for our FREE Newsletter and get:

Leave a Comment

Your email address will not be published. Required fields are marked *

Sign up for our FREE Newsletter and get:

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.

Get Best Morning Financial Newsletter... 100% Free

Best stocks ideas

Analysts’ Upgrades & Downgrades

Important Earnings

Insider Watchlist

We do not sell or share your information with anyone.

Get The Best Stocks To Trade Every Day!...100% Free

We do not sell or share your information with anyone.